TICKERNERD
Menu
APMDHealthcare · Biotechnology

APMD Stock Forecast: Apnimed, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$26
−1.88% on the day

The 4 Wall Street analysts covering Apnimed, Inc. hold a median 12-month price target of $50 — +90.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.1B
Ticker Nerd rank
1 / 100
Median analyst target
$50
Analysts covering
4
Revenue$12.1M
Operating income−$11.7M
Net income$125.9M
Free cash flow−$18.4M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.4%
1M
+5.7%
From high
−19.2%
From low
+5.7%
$25
$33
Range since 31 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

APMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
44
Revisions
36
Value
13
Growth
8
Accruals
8
Quality
4
Volatility
4
Momentum
3
Issuance
2

Size (44): Smaller than most of the companies we track.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 31 July 2026Adjusted close, US dollars
$20$30$40$50$60Aug 26Aug 26Aug 26Aug 26Aug 26Sep 26APMDHigh $60Median $50Low $41

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $41Median $50High $60

The green dot is the last close — the median target sits +90.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026B of A SecuritiesInitiatesBuy$41
25 Aug 2026Cantor FitzgeraldInitiatesOverweight$60
25 Aug 2026Evercore ISI GroupInitiatesOutperform—
25 Aug 2026LifeSci CapitalInitiatesOutperform$50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

APMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

APMD vs S&P 500, last 12 monthsTotal return, rebased to 100
95100105110115120125130Aug 26Aug 26Aug 26Aug 26Aug 26Sep 26APMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Apnimed, Inc. (APMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.6×

Cheaper than 66% of US stocks

Price / sales
9.5×

Cheaper than 15% of US stocks

Price / book
−5.9×

Cheaper than 97% of US stocks

EV / EBITDA
35.3×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
−29.4%

Higher than 9% of US stocks

Earnings growth (YoY)
—
Gross margin
90.0%

Higher than 96% of US stocks

Operating margin
−96.9%

Higher than 14% of US stocks

Net margin
142.1%

Higher than 99% of US stocks

Returns & dividend
Return on equity
0.3%

Higher than 44% of US stocks

Return on assets
−1.3%

Higher than 39% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apnimed, Inc. (APMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Apnimed, Inc. has a market value of $1.1B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $117.1M. The latest quarter shrank 29.4% year on year.

  • Net income over the same four quarters: $98.2M, a 83.8% net margin.

  • Diluted earnings per share, trailing twelve months: $1.87.

  • Free cash flow in the twelve months to 30 June 2026: −$84.1M.

  • Shares outstanding: 39.8M.

  • Trailing P/E: 4.6×; forward P/E: −6.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Apnimed, Inc. employs 81 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

APMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APMDApnimed, Inc.$1.1B
1
OBXObsidian Therapeutics, Inc.$1.1B
56
CRVSCorvus Pharmaceuticals, Inc.$1.1B
54
JBIOJade Biosciences, Inc.$1.1B
24
SVRASavara, Inc.$1.0B
35
ATTOAttovia Therapeutics, Inc.$1.0B
0
MLTXMoonLake Immunotherapeutics$1.0B
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APMD news & analysis

Apnimed: What We Know Heading Into The Feb PDUFA

Seeking Alpha · 10 Sept 2026neutral

Apnimed is a late-stage company focused on AD109 (Oxnimbi) for obstructive sleep apnea, having demonstrated Phase 3 efficacy and a manageable safety profile. Its NDA is under FDA review with a February 2027 PDUFA date, and the company holds a strong cash position with a transition from R&D to pre-commercial buildout.

Why it matters — APMD watchers would care because the February 2027 PDUFA decision for AD109 represents a key regulatory catalyst, with the company's cash runway supporting launch activities.

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 8 Sept 2026neutral

Apnimed, Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is a late-stage clinical pharmaceutical firm focused on developing oral therapies for sleep-related breathing diseases.

Why it matters — The report offers APMD watchers an update on the company's quarterly financial performance and its ongoing clinical-stage progress.

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Apnimed announced that its compensation committee granted non-qualified stock options to 10 new non-executive employees on August 31, 2026, covering an aggregate of 428,428 shares of common stock under its 2026 Inducement Plan. Each option has an exercise price of $26.85 per share, equal to the company's closing price on September 1, 2026, with vesting scheduled over four years.

Why it matters — APMD watchers would care because the inducement grants signal new employee hiring and equity compensation activity, which are relevant to share count and personnel matters.

Apnimed shares surge on bullish BofA initiation

Proactive Investors · 25 Aug 2026positive

Apnimed shares rose 8% after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target, based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), its sole asset and an oral therapy for obstructive sleep apnea.

Why it matters — Analyst coverage and the favorable rating bring added attention to Apnimed's single pipeline asset, Oxnimbi, which is the focus of the company's valuation.

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

24/7 Wall Street · 14 Aug 2026neutral

Apnimed made its Nasdaq debut, offering public investors their first pure-play opportunity in a pill-based treatment for obstructive sleep apnea (OSA).

Why it matters — The listing gives Apnimed watchers a direct public-market stake in the development of an oral alternative to CPAP machines for sleep apnea.

FAQ

Frequently asked questions about APMD stock

What is the APMD stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Apnimed, Inc. have a median 12-month price target of $50, with estimates ranging from $41 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APMD stock a buy right now?

Of the 4 analysts covering Apnimed, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apnimed, Inc. 1 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APMD?

As at 12 Sept 2026, Apnimed, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (44 of 100).

Will APMD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +90.2% from the last close, and Ticker Nerd's factor model ranks Apnimed, Inc. 1 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APMD stock forecast for 2030?

No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $60 over the next 12 months.

What does Apnimed, Inc. do?

Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea.

What is the latest news on APMD?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Apnimed: What We Know Heading Into The Feb PDUFA". Apnimed is a late-stage company focused on AD109 (Oxnimbi) for obstructive sleep apnea, having demonstrated Phase 3 efficacy and a manageable safety profile. Its NDA is under FDA review with a February 2027 PDUFA date, and the company holds a strong cash position with a transition from R&D to pre-commercial buildout.

Company

About Apnimed, Inc.

Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA. The company’s work centers on advancing medicines that may address mild, moderate, and severe forms of sleep apnea through a simplified pill-based approach. Based in Cambridge, Massachusetts, and founded in 2017, Apnimed operates within the biotechnology and sleep medicine markets, where it contributes to the development of new treatment options for patients with chronic breathing disorders during sleep.

CEO Mr. Kevin Robert Lind · 81 employees · United States · https://apnimed.com